News >

Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

Brandon Scalea
Published: Friday, Jan 11, 2019

Nina Shah, MD

Nina Shah, MD
The efficacy and safety observed with the CAR T-cell product bb21217 could help physicians get patients with heavily pretreated relapsed/refractory multiple myeloma on the path towards a cure, according to Nina Shah, MD.

According to preliminary data from the phase I CRB-402 trial (NCT03274219), presented at the 2018 ASH Annual Meeting, the anti-BCMA therapy bb21217 was safe, tolerable, and showed promising clinical activity in this patient population.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication